BridgeMD
New treatment option for Depression
Official title Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application
ClinicalTrials.gov ID: NCT03678194
What this study is testing
- What it's testing
- Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.
- Time commitment: about 6 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Age between 18 and 65 years;
- Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;
- Patients started their antidepressant treatment less than 5 days before inclusion;
- Patient treated in an outpatient setting;
- Patient informed of the diagnosis of his disease;
You likely can't join if
- A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment...
- A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;
- Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;
- Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);
- Non-comprehension of the French language
See the full eligibility criteria
- Age between 18 and 65 years;
- Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;
- Patients started their antidepressant treatment less than 5 days before inclusion;
- Patient treated in an outpatient setting;
- Patient informed of the diagnosis of his disease;
- Informed patient with written consent.
- A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;
- A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;
- Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;
- Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);
- Non-comprehension of the French language
The study team makes the final eligibility decision.
Where it's taking place
- Bordeaux, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 6 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bordeaux, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.